Physician

Hasenin Raid Hashim Al-Khersan, MD

According to 2025 Medicare claims, Hasenin Al-Khersan, MD (NPI: 1245761972) practices ophthalmology in the Houston-Pasadena-The Woodlands, TX market, with the plurality of this provider's patient population coming from Fort Bend, TX. This provider's primary affiliated billing organization is RETINA CONSULTANTS OF HOUSTON PLLC (NPI: 1619135647; TIN: 74-2109903) and primary practice location at 77479-3501.

Al-Khersan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 659 traditional Medicare patients, billed 10,806 HCPCS/CPT codes, and received $1,568,381 in Medicare payments. The top billing code was J0178 (Injection, aflibercept, 1 mg). Part D data shows 282 prescription claims across 120 beneficiaries totaling $9,384 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 89 records totaling $229,831. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$784K$1.6M2021 Medicare payment: $9,408 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $27,636 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $278,564 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,568,381 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021168176$9,408
2022288321$27,636
20232782,049$278,564
202465910,806$1,568,381

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$13K$26K2017 Drug cost: $4,765 (USD; Tot_Drug_Cst)2018 Drug cost: $6,321 (USD; Tot_Drug_Cst)2019 Drug cost: $17,305 (USD; Tot_Drug_Cst)2020 Drug cost: $21,827 (USD; Tot_Drug_Cst)2021 Drug cost: $23,157 (USD; Tot_Drug_Cst)2022 Drug cost: $25,619 (USD; Tot_Drug_Cst)2023 Drug cost: $20,401 (USD; Tot_Drug_Cst)2024 Drug cost: $9,384 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
20171344$4,765
201885150$6,321
2019118375$17,305
2020101376$21,827
2021139403$23,157
2022195582$25,619
2023143509$20,401
2024120282$9,384

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
J0178Injection, aflibercept, 1 mg1651,072$640
67028Injection of drug into eye302731$95
92014Established patient complete exam of visual system424645$87
92134Imaging of retina5721,133$29
92250Photography of the retina113148$27

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate933,115$5,180
MoxifloxacinMoxifloxacin Hcl46749$948
Ketorolac TromethamineKetorolac Tromethamine311,276$440
Atropine SulfateAtropine Sulfate14463$430
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat272,305$327

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.42$16,972Ocular Therapeutix, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.47$212,860Regeneron Pharmaceuticals, Inc.
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Hasenin Raid Hashim Al-Khersan, MD?

Tedicare shows public-source Medicare data for Hasenin Raid Hashim Al-Khersan, MD (NPI 1245761972), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hasenin Raid Hashim Al-Khersan, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Hasenin Raid Hashim Al-Khersan, MD?

Hasenin Raid Hashim Al-Khersan, MD is linked to RETINA CONSULTANTS OF HOUSTON PLLC (billing NPI 1619135647) in the available physician profile data.

Does Hasenin Raid Hashim Al-Khersan, MD have Open Payments data?

Hasenin Raid Hashim Al-Khersan, MD has 89 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.